Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
odafosfamide
- Development stage
- Phase 2
- Lead developer
- OBI Pharma
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Intravenous
01
Overview
Odafosfamide is an experimental oxazaphosphorine alkylating agent that appears to be a structural and functional analogue or derivative of ifosfamide, designed to generate cytotoxic phosphoramide mustard species that cross-link DNA and thereby inhibit DNA replication and transcription in rapidly dividing tumor cells. Like other nitrogen mustard–derived oxazaphosphorines, it is expected to act as a prodrug requiring metabolic or chemical activation to produce bifunctional alkylating metabolites that induce interstrand and intrastrand DNA cross-links at guanine N-7 positions, leading to cell-cycle arrest and apoptosis in malignant cells. Publicly available information on odafosfamide is extremely limited, and its specific developer, optimized activation pathway, pharmacokinetic properties, and clinical development program have not been clearly characterized in accessible literature.
- Other names
- OBI 3424OBI3424OBI-3424
02
Targets
AKR1C3 (Aldo-keto reductase family 1 member C3)DNA
Beyond the preview
Go deeper on odafosfamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on odafosfamide.